Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction
Richard O Cannon III
Correspondence National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10-CRC, Room 5-3330, 10 Center Drive, Bethesda, MD 20892, USA
Email cannonr@nih.gov
Although a number of therapies have been able to reduce infarct size as part of reperfusion therapy in experimental studies, the clinical results after acute myocardial infarction have not been as satisfactory. Current understanding of the mechanisms and consequences of reperfusion injury and the pharmacologic options are discussed here.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Granulocyte-colony-stimulating factor in acute myocardial infarction: future perspectives after FIRSTLINE-AMI and REVIVAL-2Nature Clinical Practice Cardiovascular Medicine Article (01 Feb 2007)
See all 3 matches for Research